SwePub
Sök i LIBRIS databas

  Extended search

id:"swepub:oai:DiVA.org:uu-93117"
 

Search: id:"swepub:oai:DiVA.org:uu-93117" > A randomized contro...

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist
  • Furuland, HansUppsala universitet,Institutionen för medicinska vetenskaper,Renal section (author)

A randomized controlled trial of haemoglobin normalization with epoetin alfa in pre-dialysis and dialysis patients

  • Article/chapterEnglish2003

Publisher, publication year, extent ...

  • Oxford University Press (OUP),2003
  • printrdacarrier

Numbers

  • LIBRIS-ID:oai:DiVA.org:uu-93117
  • https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-93117URI
  • https://doi.org/10.1093/ndt/18.2.353DOI
  • https://lup.lub.lu.se/record/891306URI

Supplementary language notes

  • Language:English
  • Summary in:English

Part of subdatabase

Classification

  • Subject category:ref swepub-contenttype
  • Subject category:art swepub-publicationtype

Notes

  • BACKGROUND: Partial correction of renal anaemia with erythropoietin improves quality of life (QoL). We aimed to examine if normalization of haemoglobin with epoetin alfa in pre-dialysis and dialysis patients further improves QoL and is safe. METHODS: 416 Scandinavian patients with renal anaemia [pre-dialysis, haemodialysis (HD) and peritoneal dialysis patients] were randomized to reach a normal haemoglobin of 135-160 g/l (n=216) or a subnormal haemoglobin of 90-120 g/l (n=200) with or without epoetin alfa. Study duration was 48-76 weeks. QoL was measured using Kidney Disease Questionnaires in 253 Swedish dialysis patients. Safety was examined in all patients. RESULTS: QoL improved, measured as a decrease in physical symptoms (P=0.02), fatigue (P=0.05), depression (P=0.01) and frustration (P=0.05) in the Swedish dialysis patients when haemoglobin was normalized. In pre-dialysis patients, diastolic blood pressure was higher in the normal compared with the subnormal haemoglobin group after 48 weeks. However, the progression rate of chronic renal failure was comparable. In the normal haemoglobin group (N-Hb), 51% had at least one serious adverse event compared with 49% in the subnormal haemoglobin group (S-Hb) (P=0.32). The incidence of thrombovascular events and vascular access thrombosis in HD patients did not differ. The mortality rate was 13.4% in the N-Hb group and 13.5% in the S-Hb group (P=0.98). Mortality decreased with increasing mean haemoglobin in both groups. CONCLUSIONS: Normalization of haemoglobin improved QoL in the subgroup of dialysis patients, appears to be safe and can be considered in many patients with end-stage renal disease.

Subject headings and genre

Added entries (persons, corporate bodies, meetings, titles ...)

  • Linde, TorbjörnUppsala universitet,Institutionen för medicinska vetenskaper(Swepub:uu)torblind (author)
  • Ahlmén, Jarl (author)
  • Christensson, AndersLund University,Lunds universitet,Internmedicin - epidemiologi,Forskargrupper vid Lunds universitet,Internal Medicine - Epidemiology,Lund University Research Groups(Swepub:lu)medf-ach (author)
  • Strömbom, Ulf (author)
  • Danielson, Bo G.Uppsala universitet,Institutionen för medicinska vetenskaper,Renal section (author)
  • Uppsala universitetInstitutionen för medicinska vetenskaper (creator_code:org_t)

Related titles

  • In:Nephrology, Dialysis and Transplantation: Oxford University Press (OUP)18:2, s. 353-3610931-05091460-2385

Internet link

Find in a library

To the university's database

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Search outside SwePub

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view